ANI Pharmaceuticals secures FDA approval, launches delayed-release naproxen

ANI Pharmaceuticals this week announced Food and Drug Administration approval to produce a delayed-release form of naproxen, the main ingredient in Aleve pain reliever. Naproxen treats moderate pain and inflammation and can be a treatment for arthritis. "ANI remains committed to driving growth through superior new product launch execution, in keeping with our purpose of 'Serving Patients, Improving Lives,'" said Nikhil Lalwani, CEO of ANI, in a statement. ANI's delayed-release naproxen is a generic version of EC-Naprosyn brand, which UK-based Pharmanovia produces. An ANI representative did not provide additional information...